Revolution Medicines (NASDAQ:RVMD) CFO Jack Anders Sells 2,753 Shares

Revolution Medicines, Inc. (NASDAQ:RVMD) CFO Jack Anders sold 2,753 shares of the stock in a transaction that occurred on Tuesday, March 17th. The stock was sold at an average price of $99.48, for a total transaction of $273,868.44. Following the sale, the chief financial officer owned 125,512 shares in the company, valued at $12,485,933.76. This represents a 2.15% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through the SEC website.

Jack Anders also recently made the following trade(s):

• On Wednesday, January 7th, Jack Anders sold 10,000 shares of Revolution Medicines stock. The stock was sold at an average price of $98.00, for a total transaction of $980,000.00.

Revolution Medicines Trading Up 1.2%

NASDAQ RVMD traded up $1.18 on Thursday, reaching $99.29. The company had a trading volume of 1,485,201 shares, compared to its average volume of 2,335,170. The business has a 50 day moving average of $103.58 and a two-hundred day moving average of $76.24. The company has a debt-to-equity ratio of 0.16, a current ratio of 7.14 and a quick ratio of 7.14. The firm has a market cap of $19.68 billion, a price-to-earnings ratio of -16.80 and a beta of 0.99. Revolution Medicines, Inc. has a fifty-two week low of $29.17 and a fifty-two week high of $124.49.

Revolution Medicines (NASDAQ:RVMD) last issued its earnings results on Wednesday, February 25th. The company reported ($1.86) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.56) by ($0.30). During the same period last year, the company posted ($1.12) earnings per share. Analysts forecast that Revolution Medicines, Inc. will post -3.49 EPS for the current year.

Analyst Ratings Changes

A number of research firms have issued reports on RVMD. Jefferies Financial Group started coverage on Revolution Medicines in a research report on Monday. They issued a “buy” rating for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Revolution Medicines in a research note on Thursday, January 22nd. Evercore raised shares of Revolution Medicines to a “strong-buy” rating in a research report on Wednesday, February 25th. Wedbush restated an “outperform” rating on shares of Revolution Medicines in a report on Friday, January 9th. Finally, Benchmark reiterated an “overweight” rating on shares of Revolution Medicines in a research note on Tuesday, February 17th. Four analysts have rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Buy” and an average price target of $78.94.

Institutional Investors Weigh In On Revolution Medicines

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the company. General Atlantic L.P. bought a new position in Revolution Medicines in the 3rd quarter worth approximately $115,556,000. Norges Bank bought a new position in Revolution Medicines during the fourth quarter valued at $195,568,000. Avoro Capital Advisors LLC bought a new stake in Revolution Medicines in the fourth quarter worth about $172,840,000. UBS Group AG boosted its holdings in Revolution Medicines by 183.6% during the 4th quarter. UBS Group AG now owns 3,087,937 shares of the company’s stock valued at $245,954,000 after acquiring an additional 1,998,972 shares during the period. Finally, Polar Capital Holdings Plc boosted its stake in shares of Revolution Medicines by 321.2% during the fourth quarter. Polar Capital Holdings Plc now owns 2,013,791 shares of the company’s stock valued at $160,398,000 after purchasing an additional 1,535,686 shares during the period. 94.34% of the stock is owned by hedge funds and other institutional investors.

About Revolution Medicines

Revolution Medicines is a clinical-stage biopharmaceutical company focused on discovering and developing small molecule therapies to treat RAS-dependent cancers and other diseases driven by the RAS/MAPK pathway. The company’s research efforts target historically “undruggable” proteins, aiming to inhibit critical nodes in cell signaling that promote tumor growth and therapeutic resistance.

The lead pipeline includes RMC-4630, a SHP2 inhibitor; RMC-6291, a selective KRAS G12C inhibitor; and RMC-6236, a pan-RAS inhibitor designed to address multiple RAS mutations.